- Home
- TORO vs STTK Comparison
TORO vs STTK Comparison
Compare TORO & STTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TORO
- STTK
- Stock Information
- Founded
- TORO 2022
- STTK 2016
- Country
- TORO Cyprus
- STTK United States
- Employees
- TORO N/A
- STTK N/A
- Industry
- TORO Marine Transportation
- STTK Biotechnology: Pharmaceutical Preparations
- Sector
- TORO Consumer Discretionary
- STTK Health Care
- Exchange
- TORO Nasdaq
- STTK Nasdaq
- Market Cap
- TORO 57.9M
- STTK 83.8M
- IPO Year
- TORO N/A
- STTK 2020
- Fundamental
- Price
- TORO $3.08
- STTK $1.94
- Analyst Decision
- TORO
- STTK Hold
- Analyst Count
- TORO 0
- STTK 6
- Target Price
- TORO N/A
- STTK $2.67
- AVG Volume (30 Days)
- TORO 27.4K
- STTK 1.6M
- Earning Date
- TORO 11-11-2025
- STTK 11-13-2025
- Dividend Yield
- TORO N/A
- STTK N/A
- EPS Growth
- TORO N/A
- STTK N/A
- EPS
- TORO N/A
- STTK N/A
- Revenue
- TORO $21,513,733.00
- STTK $2,997,000.00
- Revenue This Year
- TORO N/A
- STTK N/A
- Revenue Next Year
- TORO N/A
- STTK N/A
- P/E Ratio
- TORO N/A
- STTK N/A
- Revenue Growth
- TORO N/A
- STTK N/A
- 52 Week Low
- TORO $1.70
- STTK $0.69
- 52 Week High
- TORO $3.60
- STTK $3.95
- Technical
- Relative Strength Index (RSI)
- TORO 67.39
- STTK 64.83
- Support Level
- TORO $2.81
- STTK $1.68
- Resistance Level
- TORO $3.14
- STTK $2.01
- Average True Range (ATR)
- TORO 0.10
- STTK 0.23
- MACD
- TORO 0.04
- STTK 0.05
- Stochastic Oscillator
- TORO 88.00
- STTK 80.82
About TORO Toro Corp.
Toro Corp acquires, owns, charters, and operates oceangoing tanker vessels and provides seaborne transportation services for crude oil and refined petroleum products. It operates in three reportable segments: the Aframax tanker, the LPG carrier segment, and the Handysize tanker. The company generates maximum revenue from the Aframax tanker segment.
About STTK Shattuck Labs Inc.
Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.